Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis

Okazaki, Isao; Maruyama, Katsuya; Funatsu, Kazuo; Kashiwazaki, Kazuo; Tsuchiya, Masaharu

doi:10.1007/bf02774306

Cited by 9 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strict etiological classification among LC patients may become possible with the development of detection of the non-A, non-B hepatitis virus. The 5-year survival rate of LC patients was 62% in this study, 5&70% collectively in the collection (8), 55% (17) and 58% (18) in recent Japanese studies, 30% (16) in an English study and 5% (3) in an earlier Japanese study. The 10-year survival rate was 42% in this study, 36% (17) and 37% (18) in recent Japanese studies and 20% (16) in an English study.…”

Section: Increase Of Lc Patientssupporting

confidence: 47%

Follow‐up study of 582 liver cirrhosis patients for 26 years in Japan

Tanaka

Itoshima

Nagashima

1987

Liver

View full text Add to dashboard Cite

ABSTRACT— A long‐term follow‐up study of liver cirrhosis (LC) was performed in 582 patients diagnosed by peritoneoscopy and liver biopsy in the 26 years from 1958 to 1984. The etiology of LC consisted of hepatitis B virus (HBV) in 21%, alcoholic in 39% and cryptogenic in 39%. Fifty‐nine percent of patients had died. Causes of death were hepatocellular carcinoma (HCC 44%), liver failure (30%), rupture of esophageal varices (14%), gastrointestinal bleeding (4%) and non‐liver‐related causes (8%). HCC accounted for increasing percentages (68%) since 1980. In all groups classified by the etiology, the causes of death had the same order in incidence. The age of onset of LC increased by 10 years from 42 to 52 years old and the age of death by 15 years from 43 to 58 in the 26‐year period. The cumulative survival rate improved over the period. The 50% survival year was 7.9 in total patients, and 7.0, 8.5 and 10.0 in the three periods 1958–64, 1965–74 and 1975–84, respectively. It was 9.5, 6.3 and 9.8 in HBV, alcoholic and cryptogenic, respectively. LC patients survived 40–44% of the life expectancy of the general population in Japan in all age groups. Cox's multiregression life‐table method selected three important prognostic factors from 7 parameters: a poor prognosis with a history of heavy alcohol consumption and old age at onset, and a better prognosis with recent onset.

show abstract

Section: Increase Of Lc Patientssupporting

confidence: 47%

Follow‐up study of 582 liver cirrhosis patients for 26 years in Japan

Tanaka

Itoshima

Nagashima

1987

Liver

View full text Add to dashboard Cite

show abstract

“…In the same study, 19 patients died within the first 2 years of follow up, giving an annual mortality rate of 9.9%, 48 with a corresponding 5‐year mortality rate of 41%, compared with the mortality rate of 67% reported by a Japanese study involving 56 patients with decompensated cirrhosis 46 . In the latter study, the estimated annual mortality rate was 20%.…”

Section: Resultsmentioning

confidence: 83%

“…Seven studies were identified reporting mortality rates among patients with cirrhosis 29,39 , 40,43 , 45–47 . The annual mortality rates derived from major studies were between 3.1 and 8.0%.…”

Section: Resultsmentioning

confidence: 99%

Chronic hepatitis B virus infection in the Asia–Pacific region and Africa: Review of disease progression

Lin

Robinson

Thursz

et al. 2005

J of Gastro and Hepatol

View full text Add to dashboard Cite

Countries in the the Asia-Pacific region and Africa tend to have the highest prevalence of hepatitis B infection worldwide. Hepatitis B infection progresses from an asymptomatic persistently infected status to chronic hepatitis B, cirrhosis, decompensated liver disease and/or hepatocellular carcinoma. The aim of this review was to summarize rates and risk factors for progression between disease states in the Asia-Pacific region and Africa. A literature search was conducted employing MEDLINE and EMBASE (1975-2003) using the following key words: hepatitis B, natural history, disease progression, cirrhosis, hepatocellular carcinoma, mortality, Africa and the Asia-Pacific region. Bibliographies of articles reviewed were also searched. Ranges for annual progression rates were: (i) asymptomatic persistent infection to chronic hepatitis B, 0.84-2.7%; (ii) chronic hepatitis B to cirrhosis, 1.0-2.4%; and (iii) cirrhosis to hepatocellular carcinoma, 3.0-6.6%. Patients with asymptomatic persistent infection and chronic hepatitis B had relatively low 5-year mortality rates (<4%); rates (>50%) were much higher in patients with decompensated liver disease and hepatocellular carcinoma. No data were found for progression rates in African populations. Hepatitis B e antigen was a risk factor for chronic hepatitis B, and bridging hepatic necrosis in chronic hepatitis B increased the risk of cirrhosis. Risk factors for hepatocellular carcinoma included cirrhosis, co-infection with hepatitis C virus, and genetic and environmental factors. In this review, wide ranges of disease progression estimates are documented, emphasizing the need for further studies, particularly in Africa, where progression rates are largely not available. Summarizing information on factors associated with disease progression should assist in focusing efforts to arrest the disease process in those at most risk.

show abstract

“…Observational cohort studies of compensated cirrhosis that were reported in the English language included the following: diseased populations evaluated at tertiary referral centers, study periods between the years 1958 and 1990, predominant hepatic disease etiologies including alcohol and chronic viral hepatitis, and patient follow-up rates greater than 80%. 3 From reported investigations of large cohorts, [4][5][6][7][8][9][10][11][12][13][14][15][16][17] the median survival of patients with compensated cirrhosis is estimated at between 7 and 10 years from the time of diagnosis. Nearly 100% of individuals affected by compensated cirrhosis from chronic viral hepatitis can expect to survive at least 2 to 5 years after diagnosis 7,9,[13][14][15][16][17] (Figure 1).…”

Section: Natural History and Prognosis Compensated Cirrhosismentioning

confidence: 99%

Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis

Talwalkar¹,

Kamath²

2005

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Cirrhosis and its disease-related complications are the 12th leading cause of mortality among U.S. adults and are the 5th leading cause of death for individuals aged 45 to 54 years. Hospitalization costs for disease-related complications are estimated at 18,000 dollars per episode of care, and 10% of admitted patients die. Despite these ominous findings, the survival rate of patients with cirrhosis has improved during the past 2 decades. This observation coincides with the conducting and reporting of high-quality randomized controlled trials and observational studies. Therefore, the improved prognosis in cirrhosis may be related to the effective translation of research findings to clinical practice for this patient population. Although explicit data to support this claim are not available, this article reviews the reported trends in clinical outcomes for patients with cirrhosis and the existence of evidence-based medical information that is available to care for these chronically ill patients.

show abstract

Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis

Cited by 9 publications

References 3 publications

Follow‐up study of 582 liver cirrhosis patients for 26 years in Japan

Follow‐up study of 582 liver cirrhosis patients for 26 years in Japan

Chronic hepatitis B virus infection in the Asia–Pacific region and Africa: Review of disease progression

Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis

Contact Info

Product

Resources

About